GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719

First Posted Date: 2008-08-12

Last Posted Date: 2016-11-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT00732472

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: topotecan
Drug: pazopanib

First Posted Date: 2008-08-12

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 68

Registration Number: NCT00732420

Locations: 🇳🇱
GSK Investigational Site, Utrecht, Netherlands

A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2008-08-11

Last Posted Date: 2016-12-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT00731822

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
Biological: Thiomersal free trivalent influenza split vaccine 2003/2004

First Posted Date: 2008-08-11

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 157

Registration Number: NCT00731393

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Phase 4

Terminated

Conditions: Human Papillomavirus Infection Leading to Cervical Cancer

Interventions: Biological: Cervarix

First Posted Date: 2008-08-08

Last Posted Date: 2019-11-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 743

Registration Number: NCT00730847

Locations: 🇵🇭
GSK Investigational Site, Makati City, Philippines

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Phase 2

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: Fluticasone Furoate Nasal Spray
Other: Placebo Nasal Spray

First Posted Date: 2008-08-08

Last Posted Date: 2017-04-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 102

Registration Number: NCT00730756

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Thiomersal free trivalent influenza split vaccine 2002/2003
Biological: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003

First Posted Date: 2008-08-08

Last Posted Date: 2008-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 239

Registration Number: NCT00731029

Locations: 🇩🇪
GSK Clinical Trials Call Center, Dresden, Germany

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Phase 1

Completed

Conditions: Tuberculosis (TB)

Interventions: Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342

First Posted Date: 2008-08-08

Last Posted Date: 2008-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00730795

Locations: 🇺🇸
GSK Clinical Trials Call Center, Tacoma, Washington, United States

A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model

Phase 1

Completed

Conditions: Rhinitis

Interventions: Other: Caspaicin
Drug: Placebo
Drug: SB-705498

First Posted Date: 2008-08-08

Last Posted Date: 2017-07-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT00731250

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

Phase 2

Completed

Conditions: Infections, Rotavirus

Interventions: Biological: Human Rotavirus Vaccine - two different formulations
Biological: Prevnar
Biological: IPOL
Biological: Infanrix
Biological: OmniHIB
Biological: Pentacel

First Posted Date: 2008-08-06

Last Posted Date: 2016-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 529

Registration Number: NCT00729001

Home Terms & Conditions Privacy Policy